Subscribe
shutterstock_685347493_katherine_welles
Katherine Welles / Shutterstock.com
27 August 2020Americas

BMS to acquire Forbius in oncology expansion

Bristol Myers Squibb (BMS) has announced a deal to acquire protein engineering company  Forbius, including its portfolio of protein inhibitors.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
BMS partners with drug accelerator to launch biotech
5 February 2020   Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.
Americas
Bristol-Myers Squibb to acquire Celgene in $74bn deal
3 January 2019   American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.
Generics
Sigmapharm to appeal Pfizer and BMS’ Eliquis win
3 September 2020   Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
BMS partners with drug accelerator to launch biotech
5 February 2020   Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.
Americas
Bristol-Myers Squibb to acquire Celgene in $74bn deal
3 January 2019   American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.
Generics
Sigmapharm to appeal Pfizer and BMS’ Eliquis win
3 September 2020   Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.

More on this story

Americas
BMS partners with drug accelerator to launch biotech
5 February 2020   Bristol-Myers Squibb and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.
Americas
Bristol-Myers Squibb to acquire Celgene in $74bn deal
3 January 2019   American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.
Generics
Sigmapharm to appeal Pfizer and BMS’ Eliquis win
3 September 2020   Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York